Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Tumor hypoxia, a common feature in solid tumors, promotes cancer cell aggressiveness, metastasis, and survival.
• Molecularly targeted therapies aim to exploit cancer-specific vulnerabilities while sparing normal tissues.
• Intratumor hypoxia activates pathways crucial for cancer cell survival and therapeutic resistance.

Purpose of the Study:

• To explore a novel combination therapy targeting intratumor hypoxia.
• To investigate the rationale for concurrently inhibiting Hypoxia-Inducible Factor 1 (HIF-1) and Vascular Endothelial Growth Factor (VEGF).
• To propose a strategy to block compensatory survival circuits in cancer cells.

Main Methods:

• Review of existing therapeutic strategies targeting hypoxia-associated pathways.
• Discussion of the mechanistic links between HIF-1, VEGF, and intratumor hypoxia.
• Analysis of potential synergistic effects and counter-balancing of resistance mechanisms.

Main Results:

• Hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor (VEGF) are mechanistically linked to intratumor hypoxia.
• Concurrent inhibition of HIF-1 and VEGF presents a logical therapeutic combination.
• This combination may overcome intrinsic limitations of individual inhibitors and acquired resistance.

Conclusions:

• Concurrent inhibition of HIF-1 and VEGF offers a promising strategy for treating solid tumors.
• This approach targets compensatory survival pathways exploited by cancer cells under hypoxic stress.
• The combination's efficacy may be independent of specific genetic alterations in various solid tumors.